It has been reported that the response to alloantigens presented by the direct and indirect pathway may be of differential relevance after human kidney transplantation. Accordingly, we monitored these routes in peripheral blood mononuclear cells (PBMC) of heart transplant patients from before transplantation and up to 2 years thereafter in an attempt to find a correlation with the clinical status of the patients.
nominal antigen and persisted after transplantation, although the proportion of PBMC samples responding was significantly suppressed, irrespective of the occurrence of rejection. Consequently, complete removal of antigen-presenting cells from the stimulator population in a mixed lymphocyte culture with PBMC as responder is not a suitable tool for measuring indirect presentation of alloantigens, and therefore not relevant for monitoring the immunological status of heart transplant recipients.
The development of alloreactive effector cells participating in allograft rejection is dependent on the presence of T helper cells. These T helper cells may respond to alloantigens presented by antigen-presenting cells(APC *) via either the direct or the indirect pathway(reviewed by Sayegh) (1). The direct presentation pathway involves a direct activation of the recipient T cells by donor APC (dAPC).
For the indirect pathway, donor MHC molecules are internalized by recipient APC (rAPC), subsequently processed into peptides which are bound by recipient's MHC class II molecules, and finally presented at the cell surface of the rAPC to self-MHCrestricted, allopeptide-specific responder cells. This pathway is identical to the presentation of nominal antigens, e.g., tetanus toxoid(TET).
Both presentation pathways were found to be able to induce an alloresponse by peripheral blood mononuclear cells (PBMC) of healthy volunteers (2) . In renal transplant recipients with stable graft function, the direct pathway was not different from that of healthy donors, whereas these patients showed no response to antigens presented via the indirect pathway. When the latter reactivity was addition, it was demonstrated that the indirect pathway was more sensitive to immunosuppression than the direct route of alloantigen presentation (4, 5) .
In the present study, we monitored the presence of both antigen presentation pathways in PBMC of human cardiac transplant recipients, by measuring the proliferative response of their cells to alloantigens in mixed lymphocyte cultures (MLC). PBMC were collected longitudinally from the time of transplantation to 2 years thereafter. The presentation pathways were investigated in an attempt to find a correlation with the immunological status of the patients and possibly to obtain a relevant tool to monitor the effect of tapering of immunosuppression on the donordirected immune response. PBMC were isolated from heparinized blood by density gradient centrifugation using Ficoll-Paque (Pharmacia Biotech AB, Uppsala, Sweden). The PBMC were collected from the interphase, washed twice with HBSS (Gibco BRL, Scotland, UK), and frozen at -140°C until use. Spleen cells were obtained by mechanical dissociation of small pieces of spleen through a sieve of stainless steel in RPMI 1640-DM supplemented with 4 mM l-glutamine, 100 IU/ml penicillin, 100µg/ml streptomycin (all from Gibco, Paisley, Scotland), and 10% pooled heat-inactivated human AB serum (i.e., culture medium). DNase (10µg/ml, Boehringer Mannheim GmbH, Germany) was added to prevent aggregation of cells. Subsequently, the cell suspension was filtrated through a 70-µm cell strainer (Falcon, Franklin Lakes, NJ) and washed. Thereafter, the cells were centrifuged over a Ficoll-Paque density gradient and stored at-140°C.
To test the response to alloantigens presented via the direct or the indirect presentation route, we stimulated PBMC from the transplant recipient with spleen cells derived from the heart donor (direct route) or with donor spleen cells depleted for dAPC (indirect route). The response to TET (RIVM, Bilthoven, the Netherlands) served as positive control for the indirect presentation pathway.
To remove all dAPC, 10 7 donor spleen cells (in 3. The results of the MLC and TET stimulation are shown in Table 1 . Most PBMC samples taken before heart transplantation (HTx) reacted to both nondepleted donor spleen cells (88%) and TET (75%), but never to spleen cells depleted for dAPC. Similarly, after HTx, 75% (45/60) of the PBMC samples did respond to spleen cells not depleted for dAPC, but not to the depleted population, independent of time after transplantation or occurrence of rejection (ISHLT grade 3 or more)(7). In Table 1 contrast, the response to TET changed both after HTx compared with before HTx, and during the posttransplantation follow-up period. During the first year after HTx, only 13% (6/47) of the PBMC samples reacted to TET, which is significantly less than before HTx(P<0.001). During rejection and nonrejection episodes, no significant difference in the TET response was observed (P=0.33). Also, no difference between the first and the second year after HTx was found with regard to the TET response of samples taken during rejection. In contrast, in periods without rejection, a trend was observed in time after HTx, i.e., the TET response was more frequently observed during the second year (27%) compared with the first year (9%) after transplantation(P=0.15). An explanation for the positive responses of PBMC to the nondepleted cells and the negative responses of PBMC to the dAPC-depleted population, however, remains that the direct presentation pathway is responsible for the strong proliferative responses seen in vitro by a high frequency of T cell precursors responding to allogeneic MHC molecules (10) . The MLC used may not be sensitive enough for a detectable response to alloantigens presented via the indirect pathway to antigenspecific T cells that may be present at low frequencies. This was also reported by Watschinger et al. (11) , who indicated that T cells primed in vivo by a vascularized cardiac allograft are able to proliferate in vitro to specific peptides but only when presented by APC, which were preincubated with the allopeptide. Therefore, we used a limiting dilution analysis assay to determine the HTL frequencies. This assay is thought to be more sensitive than MLC to measure responses to directly and indirectly presented antigens. We tested 4 pre-HTx samples, because the highest responses were expected at that point in time (2) . All PBMC reacted clearly to their In summary, no difference in response of PBMC to alloantigens presented via the direct presentation pathway was detected before or after HTx, irrespective of the occurrence of rejection, and a reaction to indirectly presented alloantigens was never found. However, the response to TET remained detectable after HTx, although in significantly less cases, but again irrespective of rejection. We conclude that monitoring the direct and indirect alloantigen presentation routes in PBMC is not useful as a tool for monitoring the immunological status of heart transplant recipients.
